SYRE
Spyre Therapeutics Inc.
93.20$
+3.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +8.5% | -21.3% | +50.6% | -14.7% | +17.5% | +1.9% | +57.5% | – | – | – | – | – | – | – | – | – | – | – | – | -89.8% | +160.5% | -62.6% | -54.1% | -72.2% | -3.4% | +17.9% | +247.5% | -100.0% | – | -100.0% | – | – | – | – | – | – | – | -100.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +9.4% | -96.6% | -1.0% | -4.4% | +5.7% | -2.4% | +11.8% | -24.1% | – | – | – | – | – | – | – | – | – | +0.0% | – | – | – | |
| – | +8.5% | -21.3% | +50.6% | -14.7% | +17.5% | +1.9% | +57.5% | – | – | – | – | – | – | – | – | – | – | – | – | -11,599.1% | – | -72.5% | -82.7% | -318.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -12.0% | +4.4% | +17.9% | +6.9% | -7.2% | +18.6% | +32.8% | -2.1% | +32.1% | +22.0% | +2.9% | +20.5% | -1.5% | -17.1% | +15.8% | -26.2% | +26.5% | -24.8% | +14.5% | +9.4% | +13.0% | +1.2% | -9.5% | -22.1% | +19.0% | -3.3% | +26.2% | +41.8% | +36.6% | +3.7% | -6.6% | +37.1% | +12.8% | -17.5% | -3.6% | +12.7% | -1.3% | +35.3% | +8.4% | – | |
| – | -0.8% | +15.4% | +0.0% | +27.7% | -23.3% | +24.5% | +1.4% | +13.3% | +5.8% | -6.8% | +16.8% | +12.9% | +0.8% | +2.7% | +5.2% | +20.9% | +23.8% | -9.5% | +7.4% | +0.2% | – | – | – | – | -26.9% | +2.9% | +130.7% | -28.8% | +63.9% | -8.7% | -10.4% | -7.5% | +1.2% | +10.9% | -1.3% | -1.3% | +7.7% | +21.5% | +5.9% | – | |
| – | -8.9% | +7.7% | +12.1% | +12.9% | -12.4% | +20.3% | +23.5% | +1.6% | +25.0% | +15.4% | +5.5% | +18.9% | -1.1% | -13.2% | +13.3% | -15.9% | +25.7% | -20.1% | -62.5% | +0.2% | +244.8% | +7.3% | -10.8% | -18.4% | +2.2% | -2.0% | +766.6% | -88.5% | +150.4% | +4.1% | -7.6% | +25.5% | +10.6% | -12.5% | -21.7% | -72.2% | +779.8% | -55.4% | -8.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -71.7% | -11.5% | – | – | -2,422.2% | – | -194.7% | – | -57.1% | -191,633.3% | – | – | – | -94.4% | -1,600.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.